Evotec Subsidiary Gets Contract With U.S. Defense Department for Orthopoxvirus Drugs
2023年7月5日 - 4:57PM
Dow Jones News
By Cecilia Butini
A U.S.-based subsidiary of German biotechnology company Evotec
has won a contract with the Defense Department to develop drugs
targeting orthopoxviruses, a family of viruses that includes
smallpox and monkeypox, the company said Wednesday.
The contract, which was awarded to Seattle-based Just-Evotec
Biologics, is worth up to $74 million and includes the rapid
development of drug prototypes based on monoclonal antibodies. It
will support the Defense Department's Joint Program Executive
Office for Chemical, Biological, Radiological and Nuclear Defense,
the company said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 05, 2023 03:42 ET (07:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Evotec (TG:EVT)
過去 株価チャート
から 5 2024 まで 6 2024
Evotec (TG:EVT)
過去 株価チャート
から 6 2023 まで 6 2024